Lista de obras - Mia Wadelius - Dominio Público Uruguay

5alpha-reductase 2 polymorphisms as risk factors in prostate cancer

artículo científico publicado en 2002

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children

artículo científico publicado en 2015

A Genome-Wide Association Study of Bisphosphonate-Associated Atypical Femoral Fracture

artículo científico publicado en 2019

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy

artículo científico publicado en 2007

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

artículo científico publicado en 2009

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.

artículo científico publicado en 2010

A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy

artículo científico publicado en 2011

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon

artículo científico publicado en 2013

A randomized trial of genotype-guided dosing of warfarin

artículo científico publicado en 2013

A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid ⬇️

artículo científico publicado el 1 de septiembre de 1997

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

scientific article published on July 2010

Apolipoprotein E (APOE) and warfarin dosing in an Italian population

artículo científico publicado en 2005

Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients

artículo científico publicado en 2008

Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema

artículo científico publicado en 2017

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study

artículo científico publicado en 2016

Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans

artículo científico publicado en 2012

Association of warfarin dose with genes involved in its action and metabolism

artículo científico publicado en 2006

CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia

artículo científico

CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

scientific article published on 01 November 2019

CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum

artículo científico publicado en 2004

Can mutations in ELA2, neutrophil elastase expression or differential cell toxicity explain sulphasalazine-induced agranulocytosis?

artículo científico publicado en 2004

Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients

artículo científico publicado en 2014

Characterizing variability in warfarin dose requirements in children using modelling and simulation

artículo científico publicado en 2014

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update

artículo científico publicado en 2017

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

artículo científico publicado en 2011

Clinical factors predicting drug-induced liver injury due to flucloxacillin

artículo científico publicado en 2018

Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans

artículo científico publicado en 2017

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

artículo científico publicado en 2005

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis

artículo científico publicado en 2018

Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough

artículo científico publicado en 2016

Corrigendum to "Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema".

artículo científico publicado en 2018

Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation

artículo científico publicado en 2013

Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden

artículo científico publicado en 2016

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

artículo científico

Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology

artículo científico publicado en 2002

Erratum to: Warfarin dose prediction in children using pharmacometric bridging – comparison with published pharmacogenetic dosing algorithms.

artículo científico publicado en 2013

Functional role of P-glycoprotein in the human blood-placental barrier

artículo científico publicado en 2005

Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy

Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing

artículo científico publicado en 2005

Genetic determinants of dabigatran plasma levels and their relation to bleeding

artículo científico publicado en 2013

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy

artículo científico publicado en 2016

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis

artículo científico publicado en 2014

Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population

artículo científico publicado en 2017

Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population

artículo científico publicado en 2016

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study

artículo científico publicado en 2013

Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations

artículo científico publicado en 2020

Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment

artículo científico publicado en 2020

Genome-wide association study of warfarin maintenance dose in a Brazilian sample

artículo científico publicado en 2015

Genotype-guided dosing of vitamin K antagonists

artículo científico publicado en 2014

Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes

artículo científico publicado en 2011

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process

artículo científico publicado en 2014

Induction of CYP2D6 in pregnancy*

artículo científico publicado el 1 de octubre de 1997

Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis

artículo científico publicado en 2016

Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta

artículo científico publicado en 2008

Integration of genetic, clinical, and INR data to refine warfarin dosing

artículo científico publicado en 2010

Lamotrigine and toxic epidermal necrolysis

scientific article published on 01 October 1996

MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis

artículo científico publicado en 2020

Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice

scientific article published on 22 April 2019

Narcolepsy risk loci are enriched in immune cells and suggest autoimmune modulation of the T cell receptor repertoire

Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose

artículo científico publicado en 2016

Oral anticoagulation: a critique of recent advances and controversies

artículo científico publicado en 2015

Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival

article

Patients benefit from genetics-guided coumarin anticoagulant therapy

artículo científico publicado en 2014

Pharmacogenetic analysis can predict adverse effects of statins

artículo científico publicado el 7 de mayo de 2013

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

artículo científico publicado en 2011

Pharmacogenetics of warfarin: current status and future challenges

artículo científico publicado en 2006

Pharmacogenetics-based warfarin dosing in children

artículo científico publicado en 2014

Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing

artículo científico publicado en 2011

Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing

artículo científico publicado en 2019

Phenotype standardization for statin-induced myotoxicity

artículo científico publicado en 2014

Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.

artículo científico publicado en 2014

Placental transfer of quetiapine in relation to P-glycoprotein activity

Point: use of pharmacogenetics in guiding treatment with warfarin

artículo científico publicado en 2009

Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer

artículo científico publicado en 1999

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis

artículo científico publicado en 2000

Possible fluconazole-fentanyl interaction-a case report

artículo científico publicado en 2006

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics

artículo científico publicado en 2011

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

artículo científico publicado en 2010

Prediction of warfarin dose: why, when and how?

artículo científico

Prostate cancer associated with CYP17 genotype

artículo científico publicado en 1999

Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants

artículo científico publicado en 2015

Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.

artículo científico publicado en 2009

SWEDEGENE-a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions

scientific article published on 17 January 2020

Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions

artículo científico publicado en 2019

Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus

artículo científico publicado en 2017

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

artículo científico publicado en 2014

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

artículo científico publicado en 2012

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

artículo científico

The largest prospective warfarin-treated cohort supports genetic forecasting

scientific article published on 23 June 2008

Warfarin dose prediction in children using pharmacogenetics information

artículo científico publicado en 2012

Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms

artículo científico publicado en 2013

Warfarin dose related to apolipoprotein E (APOE) genotype

artículo científico publicado en 2005

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

artículo científico publicado en 2010

Warfarin pharmacogenetics: it matters if you're black or white

artículo científico publicado en 2014

Warfarin-noscapine interaction: a series of four case reports

artículo científico publicado en 2008

[Preventive work can reduce drug side effects]

miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle

artículo científico publicado en 2012

Lista de obras de Mia Wadelius

5alpha-reductase 2 polymorphisms as risk factors in prostate cancer

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children

A Genome-Wide Association Study of Bisphosphonate-Associated Atypical Femoral Fracture

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.

A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon

A randomized trial of genotype-guided dosing of warfarin

A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid ⬇️

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

Apolipoprotein E (APOE) and warfarin dosing in an Italian population

Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients

Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study

Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans

Association of warfarin dose with genes involved in its action and metabolism

CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia

CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum

Can mutations in ELA2, neutrophil elastase expression or differential cell toxicity explain sulphasalazine-induced agranulocytosis?

Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients

Characterizing variability in warfarin dose requirements in children using modelling and simulation

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

Clinical factors predicting drug-induced liver injury due to flucloxacillin

Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis

Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough

Corrigendum to "Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema".

Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation

Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology

Erratum to: Warfarin dose prediction in children using pharmacometric bridging – comparison with published pharmacogenetic dosing algorithms.

Functional role of P-glycoprotein in the human blood-placental barrier

Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy

Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing

Genetic determinants of dabigatran plasma levels and their relation to bleeding

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis

Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population

Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study

Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations

Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment

Genome-wide association study of warfarin maintenance dose in a Brazilian sample

Genotype-guided dosing of vitamin K antagonists

Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process

Induction of CYP2D6 in pregnancy*

Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis

Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta

Integration of genetic, clinical, and INR data to refine warfarin dosing

Lamotrigine and toxic epidermal necrolysis

MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis

Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice

Narcolepsy risk loci are enriched in immune cells and suggest autoimmune modulation of the T cell receptor repertoire

Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose

Oral anticoagulation: a critique of recent advances and controversies

Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival

Patients benefit from genetics-guided coumarin anticoagulant therapy

Pharmacogenetic analysis can predict adverse effects of statins

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

Pharmacogenetics of warfarin: current status and future challenges

Pharmacogenetics-based warfarin dosing in children

Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing

Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing

Phenotype standardization for statin-induced myotoxicity

Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.

Placental transfer of quetiapine in relation to P-glycoprotein activity

Point: use of pharmacogenetics in guiding treatment with warfarin

Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis

Possible fluconazole-fentanyl interaction-a case report

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

Prediction of warfarin dose: why, when and how?